




In a further effort to extend our reach and visibility, a series of interviews was recorded at the CDRC Annual Meeting from key stakeholders within the Collaboratory. Check out Denise Robinson, Director of Research, the EHE Foundation and member of the CURE Drug Repurposing Collaboratory. She talks about the importance of drug repurposing as the EHE Foundation seeks better treatments for the very rare EHE Disease, and the importance public-private partnerships like the CDRC in fulfilling these unmet needs.

Q&A with FDA



CURE ID with Heather Stone and Dr. Marco Schito – Drug Information Update

In this podcast episode, listen to Ms. Heather Stone, FDA's health science policy analyst in the FDA's Office of Medical Policy, and Dr. Marco Schito, Executive Director of the Critical Path Institute's CURE Drug Repurposing Collaboratory (CDRC) discuss CURE ID and the exciting plans to expand the tool beyond infectious diseases. CURE ID can be found online at <https://cure.ncats.io> or it can be downloaded from the App or Play store as "CURE ID".

Listen to the podcast here: <https://lnkd.in/gFrA2VFT>

Publication Announcement

PLOS NEGLECTED TROPICAL DISEASES

OPEN ACCESS | PEER-REVIEWED

RESEARCH ARTICLE

Diagnostic capacities and treatment practices on implantation mycoses: Results from the 2022 WHO global online survey

Barbara Milani, Daniel Argaw Dagne, Hye Lynn Choi, Marco Schito, Heather Anne Stone

Between January and March 2022, WHO conducted a global online survey to collect data on diagnostic capacities and treatment practices in different settings for four implantation mycoses: eumycetoma, actinomycetoma, cutaneous sporotrichosis and chromoblastomycosis. The survey investigated the type of diagnostic methods available in countries at various health system levels (tertiary, secondary, primary level) and the medicines used to treat implantation mycoses, with a view to understanding the level of drug repurposing for treatment of these diseases.

This article is the result of a collaboration between FDA, WHO, and CDRC, thanks to the generous support of the FDA's Office of Global Policy and Strategy (OGPS). The goal of this collaboration is for WHO to help to assess which infectious diseases the CURE ID platform should focus on. The collaboration identified implantation mycoses as an area of high unmet medical need where drug repurposing could be a promising approach to identification of treatments.

Authors: Barbara Milani (WHO), Daniel Argaw Dagne (WHO/NTD), Hye Lynn Choi (WHO/NTD), Marco Schito (CDRC), Heather Anne Stone (FDA)

July Sarcoma Awareness Impact Story



In Honor of **#JulySarcomaAwarenessMonth**, CDRC wrote an Impact Story titled "By Bringing Patients' Voices to the Forefront, Sarcoma Advocates Illustrate Community's Innovative Impact" surrounding two dedicated partners, [Denise Reinke](#) and [Lisa De Young](#).

Dysautonomia International (DI) Conference

The CURE ID team was able to connect with clinicians, patients, and care partners in the Long COVID community about our work in the space and upcoming survey aimed at collecting data on use of drug repurposing in managing symptoms. They also discussed the opportunity to expand CURE ID to cover other post-infectious sequelae, like dysautonomia, POTS (postural orthostatic tachycardia syndrome), and ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome).



RASopathies Symposium

RASOPATHIES NETWORK
connect · collaborate · accelerate

8th International RASopathies Symposium: Expanding Research and Care Practice through Global Collaboration and Advocacy

Let us collaborate to accelerate the development of new treatments and improve the lives of patients with RASopathies.

RASOPATHIES NET.ORG

CDRC
CRITICAL PATH INSTITUTE

The RASopathies Network, (a patient advocacy group for a group of diseases collectively known as RASopathies), held a symposium bringing clinicians, researchers, genetic counselors, trainees, biopharma representatives, advocates, and affected RASopathy families from the international community together to discuss the current state of this rare disease.

The call for patients, care partners, and researchers to come together and share their experiences was raised repeatedly and reaffirmed the CDRC's directive to create a place where the stories, information, and insight of those struggling with a rare disease can be shared and where individuals can learn from others experiences.

Events

Critical Care Datathon
August 5-6, 2023, New York

The Society of Critical Care Medicine's (SCCM) Datathon is a collaborative event connecting clinicians with data scientists to develop pragmatic data-driven models applicable to the care of critically ill patients using de-identified critical care electronic health record datasets.

The Datathon demonstrates the multiprofessional approach required to successfully analyze large datasets. It combines medical science and data science techniques to address real-world problems using existing datasets. The Datathon is part of Discovery, the Critical Care Research Network, and is designed to synthesize critical problem solving and data analytics, promote multiprofessional collaboration, and increase data science knowledge and innovation. The goal is to identify projects that have the potential to lead to publication and improve the care of critically ill patients. Critical care clinicians, researchers, and data scientists are encouraged to participate. Clinicians do not need to have existing data science knowledge. [Register Here](#)

IDWeek 2023
Oct. 11-15, 2023, Boston

IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP). CURE ID will have a booth to visit. CURE ID and CDRC will have multiple abstracts presented. Abstracts include: The landscape of infections caused by rare bacterial pathogens, Landscape Analysis to Identify Effective Drug Repurposing Candidates for the Treatment of Implantation Mycoses: Comparison of World Health Organization Survey Treatment Data and Published Case Reports on CURE ID, and The Lesser Known Treponemal Infections: A Review of Non-Syphilitic Cases. [Register Here](#)

American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting
October 18-22, 2023, Chicago, IL

The meeting draws tropical medicine and global health professionals representing academia, foundations, government, not-for-profit organizations, non-governmental organizations, the private sector, the military, and private practice. The meeting is designed for researchers, professors, government and public health officials, military personnel, travel clinic physicians, practicing physicians in tropical medicine, students, and all healthcare providers working in the fields of tropical medicine, hygiene, and global health. CURE ID will have a booth at this conference. [Register Here](#)

INFOCUS 2023
November 15- 18, 2023, Brazil

Welcome to the 21th INFOCUS, which will be held in Iguazu Falls, Brazil, the largest waterfall system in the world. INFOCUS or The Latin American Forum of Fungal Infections in Clinical Practice was created 21 years ago, and at present constitutes the main scientific event on fungal infections in Latin America.

The INFOCUS annual meeting enables Clinicians, Microbiologists, Pharmacists, Biomedical and other Health Professionals to discuss and update everything related to fungal infections. [Register Here](#)


Trending Articles

[Long COVID: Alice Evans, brucellosis, and reflections on infectious causes of chronic disease](#)

[Drug repurposing in oncology](#)

[Low rates of antifungal therapeutic drug monitoring among inpatients who received itraconazole, posaconazole, or voriconazole, United States, 2019–2021](#)

Awareness Month



CURE ID/CDRC Social Media Ambassador


Looking to become a social media ambassador?

CURE ID is looking to recruit individuals interested in help promoting our web-based app. The platform enables healthcare providers to share their real-world experiences treating patients with repurposed drugs. We currently have 20 social media ambassadors and looking to expand.

This is an unpaid position but can win CURE ID/CDRC swag.

This is a competitive opportunity to bring on more followers, tweets, discussion posts, and win some swag!

If interested please reach out to cbassetti@c-path.org



Be Heard

Tell Your Drug Repurposing Story in 2023

Our Impact stories share the value and impact C-Path's and CDRC's work brings to patients, patient organizations, drug developers, the academic community, regulators and more. Enjoy and share! [Impact Stories](#) | [Critical Path Institute \(c-path.org\)](#)

Reach out to the Communication and Patient Engagement Manager, Claire Bassetti at cbassetti@c-path.org if interested in sharing your story through an Impact Story.

Joining the CDRC

CDRC
CURE DRUG REPURPOSING COLLABORATORY


The CURE Drug Repurposing Collaboratory (CDRC) is a public-private partnership initiated in June 2020 by C-Path and the U.S. Food and Drug Administration (FDA) in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).

If interested, please feel free to get involved with the CURE Drug Repurposing Collaboratory (CDRC), here: <https://c-path.org/cdrc>

Collaborators



Brought to you by



Visit CURE ID

Visit the **CURE ID** website for more information.
<https://cure.ncats.io>

Get the CURE ID Mobile App



You received this email because you registered for CURE ID or signed up to receive our monthly newsletter. If you have any questions regarding this communication, please contact us at curesupport@nih.gov